What is Mineralys Therapeutics, Inc. Common Stock (MLYS) stock price today?

Mineralys Therapeutics, Inc. Common Stock (MLYS) currently trades at $25.56 per share. The stock has a market capitalization of $2.11B and a P/E ratio of —x.

Is MLYS stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Mineralys Therapeutics, Inc. Common Stock has a Smart Value Score of 27/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 1/9 and Altman Z-Score is 4.15.

Is Mineralys Therapeutics, Inc. Common Stock financially healthy?

Mineralys Therapeutics, Inc. Common Stock's Piotroski F-Score is 1/9 (weak financial health). The Altman Z-Score of 4.15 places it in the safe zone.

MLYS

Mineralys Therapeutics, Inc. Common Stock

NASDAQ: MLYS · HEALTHCARE · BIOTECHNOLOGY

$25.56

-1.27% today

Updated 2026-04-29

Market cap

$2.11B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.29

Dividend yield

—

52W range

$13 – $48

Volume

1.2M

Market cap

$2.11B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.29

Dividend yield

—

52W range

$13 – $48

Volume

1.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.8

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

4.2

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$49.38

+93.19%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy8 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Altman Z 4.15 — safe zone

Risks

- Piotroski 1/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-37.90M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-29.80M	$-71.90M	$-177.81M	$-154.65M	$-32.23M
EPS	—	—	—	—	$-2.29
Free cash flow	$-29.22M	$-81.17M	$-166.41M	$-142.43M	$-37.90M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
MLYS	$2.11B	27	4.3	3.0	5.0	6.8	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Mineralys Therapeutics, Inc. Common Stock trades at $25.56. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 4.15, it sits in the safe zone.

Frequently asked questions

What is Mineralys Therapeutics, Inc. Common Stock's stock price?

Mineralys Therapeutics, Inc. Common Stock (MLYS) trades at $25.56.

Is Mineralys Therapeutics, Inc. Common Stock overvalued?

Smart Value Score 27/100 (Grade F, Strong Sell).

What is the price target of Mineralys Therapeutics, Inc. Common Stock (MLYS)?

The analyst target price is $49.38, representing +93.2% upside from the current price of $25.56.

Piotroski F-Score?

1/9 — weak financial health.

Altman Z-Score?

4.15 — safe zone.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-36.90%

Beta0.69

50D MA$27.16

200D MA$30.86

Shares out0.08B

Float0.06B

Short ratio—

Avg volume1.2M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

MLYS vs LLY →MLYS vs JNJ →MLYS vs ABBV →Stock screener →